Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer.

Higher PSA was associated with lower likelihood for molecular imaging and higher cost in a one-year time frame. Higher cost was also associated with private insurance, but there was no clear relationship between insurance type and imaging type.